Arbutus Biopharma Corporation Common Stock (ABUS)
Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing therapies for viral diseases, particularly hepatitis B virus (HBV). The company leverages its proprietary delivery technologies to create targeted treatments aimed at curing chronic HBV infections. Established with a focus on innovative antiviral solutions, Arbutus Biopharma aims to address unmet medical needs in infectious diseases.
Company News
Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The FDA has approved AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unres...